Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Akebia Therapeutics posts robust Q4 results, eyes expansion opportunities

Akebia Therapeutics showcased a strong performance in Q4 2022, highlighting revenue growth, regulatory progress, and strategic initiatives. The company faces challenges in regulatory processes and funding but is well-positioned to capitalize on opportunities for growth and innovation.

Akebia Therapeutics excels in Q1 2023, faces regulatory challenges

Akebia Therapeutics demonstrated strong performance in Q1 2023 with key achievements in product approvals and clinical study results, while also addressing revenue challenges and cost management.
The company faces challenges related to regulatory compliance and revenue decline but has opportunities to explore new therapeutic applications and strategic partnerships for growth.
Overall, Akebia's proactive approach to addressing challenges and pursuing opportunities positions it well for future success in the competitive biopharmaceutical market.

Akebia Therapeutics advances vadadustat globally, eyes U.S. launch in 2024

Akebia Therapeutics showcased operational progress and financial stability during the Q2 earnings call, emphasizing vadadustat's global potential.
While facing regulatory challenges and competitive pressures, the company's strategic partnerships and leadership confidence signal growth opportunities.
Analysts' inquiries highlighted areas for improvement, suggesting a need for clearer communication and strategic clarity in key operational areas.
Overall, Akebia remains focused on advancing vadadustat towards potential U.S. approval, positioning for future growth and market success.

Akebia Therapeutics reports strong Q3 earnings and readies for vadadustat launch

Akebia Therapeutics is poised for the potential launch of vadadustat with strong financial performance and a well-prepared commercial infrastructure.
The company faces challenges in pricing strategies and market competition but has opportunities to capture a significant share of the anemia treatment market.
Overall, Akebia Therapeutics remains focused on delivering value to patients and shareholders through vadadustat's potential success in the U.S. market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Allegheny Technologies

ATI, AKBA and ALTG have been added to the Zacks Rank #5 (Strong Sell) List on November 22, 2024.

New Strong Sell Stocks for November 22nd

Akebia Therapeutics, Inc.'s stock has surged nearly 35% after positive updates on its Vafseo (vadadustat) and promising third-quarter results, despite macroeconomic challenges. The company is expanding its market through partnerships and trials, addressing unmet needs in anemia treatment for CKD patients, and exploring label expansion. Risks include potential competition post-2025 due to patent expiration for Auryxia, but current limited competition and strong brand recognition mitigate this.

Q3 2024 Earnings: Hold Akebia Therapeutics

Akebia continues to publish important results of FO2CUS trial to further physicians' understanding of Vafseo® (vadadustat)  CAMBRIDGE, Mass. , Nov. 14, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the American Journal of Kidney Disease has published the results of FO2CUS, an open-label study evaluating the efficacy and safety of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, in hemodialysis patients who were converted from a long-acting erythropoiesis-stimulating agent (ESA) to three times weekly oral vadadustat dosing for the maintenance treatment of anemia.

Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease

CAMBRIDGE, Mass. , Nov. 12, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the Jefferies London Healthcare Conference on Thursday, November 21 at 1:00 PM GMT.

Akebia Therapeutics to Present at the Jefferies London Healthcare Conference

Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Mercedes Carrasco - Senior Director, Investor Relations John Butler - Chief Executive Officer Nick Grund - Chief Commercial Officer Erik Ostrowski - Chief Financial and Business Officer Conference Call Participants Allison Bratzel - Piper Sandler Ed Arce - H.C. Wainwright Julian Harrison - BTIG Operator Good day and thank you for standing by.

Akebia Therapeutics, Inc. (AKBA) Q3 2024 Earnings Call Transcript

Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.08 per share a year ago.

Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates

Vafseo® (vadadustat) on track for U.S. market availability expected in January 2025 Over 300,000 patients, representing approximately 60% of dialysis patient lives in the U.S., now covered under dialysis provider contracts for Vafseo Vafseo granted TDAPA reimbursement and issued a Level II Healthcare Common Procedure Coding System code Akebia to Host Conference Call at 8:00 a.m. ET on November 7 CAMBRIDGE, Mass.

Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

CAMBRIDGE, Mass. , Nov. 1, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three newly-hired employees options to purchase an aggregate of 20,000 shares of Akebia's common stock on October 31, 2024.

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia to Host Conference Call on November 7, 2024, at 8:00 a.m. EST CAMBRIDGE, Mass.

Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights

Contract in place with a comprehensive kidney care provider serving more than 200,000 patients at its thousands of U.S. dialysis centers  CAMBRIDGE, Mass. , Oct. 22, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has signed a multi-year commercial contract with one of the nation's leading providers of kidney care services, expanding access to Vafseo® (vadadustat) for patients on dialysis.

Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis

Vadadustat clinical data on display for nephrologist and healthcare providers in advance of U.S. market availability expected in January 2025 CAMBRIDGE, Mass. , Oct. 15, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the American Society of Nephrology Kidney Week 2024 (ASN Kidney Week), which will take place in San Diego, CA from October 24-27.

Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024

Designed to help dialysis organizations incorporate new treatments into their practices, TDAPA provides two years of reimbursement in addition to the ESRD bundled rate A HCPCS code has also been assigned to Vafseo to facilitate reimbursement at dialysis organizations CAMBRIDGE, Mass. , Oct. 10, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the Center for Medicare & Medicaid Services (CMS) has determined that Vafseo® (vadadustat) meets the criteria for the Transitional Drug Add-On Payment Adjustment (TDAPA) in the anemia management end-stage renal disease (ESRD) prospective payment system functional category, beginning on January 1, 2025.

CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025

U.S. Renal Care is a leading provider of in-center and home dialysis in the United States CAMBRIDGE, Mass. , Oct. 7, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, and U.S. Renal Care (USRC), the nation's fastest-growing dialysis provider, today announced entry into a multi-year commercial supply contract encompassing all USRC dialysis centers.

Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis

Outcomes study will assess mortality and hospitalization in patients treated with Vafseo compared to current standard of care Trial aims to build a body of real-world evidence to understand the potential benefits of treating patients with Vafseo CAMBRIDGE, Mass. , Sept. 5, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, and U.S. Renal Care (USRC), the nation's largest privately held and fastest-growing kidney care provider, today announced plans to begin a collaborative clinical trial of recently approved Vafseo.

Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis

Here, we discuss some reasons why buying Akebia (AKBA) stock now may turn out to be a prudent move.

Here's Why You Should Consider Buying Akebia (AKBA) Stock

CAMBRIDGE, Mass. , Aug. 26, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that its executives will participate in two investor conferences in September: Wells Fargo Healthcare Conference on September 4-6, 2024 in Boston and H.C.

Akebia Therapeutics to Present at Upcoming Investor Conferences

Amneal Pharmaceuticals

Bioventus

Corcept Therapeutics

Foghorn Therapeutics

Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, BVS, FHTX, and AKBA may prove to be good additions to one's portfolio.

5 Small Drug Stocks to Buy as Innovation Reaches Peak

Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Mercedes Carrasco - Senior Director, Investor Relations John Butler - President and Chief Executive Officer Nicholas Grund - Senior Vice President, Chief Commercial Officer Erik Ostrowski - Senior Vice President, Chief Financial Officer and Chief Business Officer Conference Call Participants Julian Harrison - BTIG Ed Arce - H.C. Wainwright Operator Thank you for standing by.

Akebia Therapeutics, Inc. (AKBA) Q2 2024 Earnings Call Transcript

Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.06 per share a year ago.

Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates

Vafseo ® (vadadustat) Tablets market availability on track for January 2025 TDAPA application submission and WAC pricing announcement for Vafseo complete Second quarter 2024 Auryxia® (ferric citrate) net product revenues of $41.2 million Akebia to host conference call at 8:00 a.m. ET on August 8 CAMBRIDGE, Mass.

Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Akebia to Host Conference Call on August 8, 2024, at 8:00 a.m. ET CAMBRIDGE, Mass.

Akebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights

Akebia regains full rights to sell Vafseo® (vadadustat) Tablets in the U.S. following the execution of a royalty-based termination agreement with CSL Vifor to simplify operational execution and improve economics Announced Vafseo WAC pricing of $1,278 for a 30-day supply Submitted TDAPA application for Vafseo in June 2024 and expects designation on January 1, 2025 Akebia to host investor conference call at 8:00 a.m. ET on July 11, 2024 CAMBRIDGE, Mass.

Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets

CAMBRIDGE, Mass. , June 27, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in the H.C.

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

CAMBRIDGE, Mass. , June 24, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Erik Ostrowski as Senior Vice President, Chief Financial Officer and Chief Business Officer.

Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer

CAMBRIDGE, Mass. , May 23, 2024 /PRNewswire/ --  Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on Wednesday, June 5 at 9:00 a.m.

News for Akebia Therapeutics Stock (AKBA)